Skip to main content
NCBI home page
FEBS Open Bio logoLink to FEBS Open Bio
. 2017 Aug 16;7(9):1316–1327. doi: 10.1002/2211-5463.12268

A modified graft‐versus‐host‐induced model for systemic sclerosis, with pulmonary fibrosis in Rag2‐deficient mice

Xue Yang 1,2,3,[Link], Chi Liu 2,[Link], Masayuki Fujino 2,4, Ji Yang 5, Xiao‐Kang Li 2,3,✉, Hejian Zou 1,3,✉
PMCID: PMC5586340  PMID: 28904861

Abstract

Systemic sclerosis (SSc) is a connective tissue disease that results in fibrosis in multiple organs. Various animal models for this disease have been developed, both genetic and induced. One of the induced models, sclerodermatous graft‐versus‐host disease (scl‐GvHD), exhibits the main characteristics of SSc, but involves lethal γ‐irradiation of recipients. We sought to develop a modified scl‐GvHD model. Spleen cells from B10.D2 donor mice were transplanted into immunodeficient Rag‐2 recipients on the BALB/c genetic background. Tissue fibrosis was analyzed at 3 and 9 weeks after transplantation. In addition to serum levels of anti‐Scl‐70 autoantibody and cytokines, tissue inflammation, fibrosis, expression of collagen‐I and α‐smooth muscle actin (α‐SMA), infiltration of leukocytes, mRNA expression of transforming growth factor (TGF)‐β, collagen‐I, α‐SMA, tumor necrosis factor (TNF)‐α, and interleukin (IL)‐6, the classical signal pathway of TGF‐β, Smad‐3, and p‐Smad‐3 expression in tissue were analyzed. Skin thickening and increased collagen synthesis, as well as the manifestation of tissue fibrosis, could be detected in skin, kidney, and lung of modified scl‐GvHD mouse model. Increased serum levels of anti‐Scl‐70 autoantibody, IL‐10, and TGF‐β could be detected. Increased CD4+ T cells and F4/80+ macrophage infiltration were found in skin, kidney, and lung. Gene expression of collagen‐I, TGF‐β, α‐SMA, TNF‐α, and IL‐6 was increased in tissue of the scl‐GvHD model. Moreover, TGF‐β expression and Smad‐3 phosphorylation were detected in skin, kidney, and lung of scl‐GvHD mice. Our data show that spleen cells from B10.D2 donor mice transplanted into immunodeficient Rag‐2 recipients could induce typical fibrosis not only of the skin and kidney but also of lung, which was missing from previous scl‐GvHD models. Thus, the modified scl‐GvHD model might be a promising model to explore the immunologic mechanisms of SSc and may be useful for investigation of new therapies for systemic sclerosis.

Keywords: fibrosis, graft‐versus‐host disease, systemic sclerosis

Abbreviations

α‐SMA

α‐smooth muscle actin

IL

interleukin

qRT‐PCR

Quantitative reverse transcription‐polymerase chain reaction

Rag‐2

recombination‐activating gene 2

scl‐GvHD

sclerodermatous graft‐versus‐host disease

SSc

systemic sclerosis

TGF‐β

transforming growth factor‐β

TNF‐α

tumor necrosis factor‐α

Systemic sclerosis (SSc) is a connective tissue disease characterized by increased collagen synthesis and deposition, skin thickening, fibrosis of organs including the liver, kidney, intestinal tract, and lung, and widespread vasculopathy. SSc is distinctly characterized by the progressive interstitial and perivascular fibrosis 1. SSc is considered incurable. In particular, diffuse fibrosis and the interstitial pneumonia after infection are the biggest highest risks of fatality in SSc.

Although SSc has been studied intensively, the initial pathogenesis remains unclear. Viruses, drugs, environmental, and occupational exposures to organic solvents, vinyl chloride, and silicate have been considered to be the etiology of SSc 2. Furthermore, immune dysfunction is known to contribute to the autoimmune injuries in SSc 2, 3, 4, 5.

To elucidate the pathogenesis of SSc for the development of new therapeutic approaches and medicine, an animal model that can comprehensively mimic the disease is needed. This model should have the typical characteristics of SSc, including dermal thickening, progressive fibrosis of internal organs, vascularity markers, and autoantibodies. To date, several genetic and inducible animal models of SSc have been developed and are available for research 6. Animal models for SSc can be classified into two types. The first is genetic models, which mainly include Cre‐ER and TBRIIΔk mice, Fra‐2 transgenic mice, tight skin‐1 and ‐2 mouse models, and UCD‐200 chicken. The second is inducible models, which include topoisomerase‐I‐ and CFA‐induced fibrosis, hypochlorous acid‐induced fibrosis, bleomycin‐induced fibrosis, and sclerodermatous graft‐versus‐host disease (scl‐GvHD) 7. Each type of animal model has its own advantages and limitations 8. Among these animal models, scl‐GvHD model could comprehensively exhibit the three main features of the disease, namely vasculopathy, immune dysregulation, and dermal and internal organ fibrosis 1.

scl‐GvHD represents a distinctive phenotype of chronic GvHD first described in 1977 9. The scl‐GvHD model is considered to be one of the best for SSc studies because it can mimic most of the characteristics of SSc, including dermal thickening in extremities, overproduction of collagen, circulating autoantibodies, and internal organ fibrosis. Traditional scl‐GvHD was carried out by the transplantation of bone marrow and spleen cells from B10.D2 donor into BALB/c recipient mice following lethal γ‐irradiation of recipients 10. Two weeks after bone marrow and spleen cells transplantation, inflammatory cells infiltrate affected tissues and stimulate resident fibroblasts to release large amounts of collagen, resulting in tissue fibrosis. Notably, in the synthesis of an scl‐GvHD model, lethal γ‐irradiation of recipients always leads to death. Therefore, a stable, convenient, and feasible scl‐GvHD mouse model is needed. In this study, we created a modified model of scl‐GvHD using immunodeficient recombination‐activating gene 2 (Rag‐2) recipient mice.

Materials and methods

Animals

Female normal BALB/c (H2d) mice and B10.D2 mice (H2d) were purchased from Japan SLC, Inc (Shizuoka, Japan). Rag‐2‐KO mice on the BALB/c (H2d) background were kindly obtained from S. Nakae (The University of Tokyo). All mice were enrolled between 10 and 12 weeks of age and were maintained under standard conditions. Rodent food, water, and all animal manipulations were performed according to the recommendations of the Committee of the Care and Use of Laboratory Animals at the National Research Institute for Child Health and Development, Tokyo, Japan (Permission Number: 2002‐003).

Scl‐GvHD model

Spleens were aseptically collected from BALB/c and B10.D2 mice separately. A single‐cell suspension was generated from dissociated spleen by rubbing. Erythrocytes were lysed in 10 × PBS and pure water, and living cells were counted by trypan blue dye exclusion assay on a cytometer. The splenocytes were resuspended in RPMI 1640 (Gibco BRL, Grand Island, NY, USA) and were purified by density gradient centrifugation using lympholyte‐M (Cedarlane Ltd, Burlington, ON, Canada). Cells were passed via a 75‐μm nylon mesh cell filter to obviate large debris. Splenocytes (4 × 107) collected from B10.D2 mice (scl‐GvHD group) or BALB/c mice (control group) were transplanted intravenously into recipient Rag‐2‐KO mice.

Histological analysis

Hematoxylin and eosin (H&E) staining, standard Masson trichrome histochemical staining, immunofluorescence analysis for collagen‐I deposition and α‐smooth muscle actin (α‐SMA) expression, and immunohistochemical analysis for the measurement of CD4+ T lymphocytes and F4/80+ macrophages infiltration were performed as previously reported 11, 12, 13. Histological dermal thickness, lung fibrosis, and hydroxyproline contents were determined as described previously 14.

ELISA

Concentration of anti‐Scl‐70 autoantibody in serum was determined by ELISA (IBL, Gunma, Japan). Interleukin (IL)‐10 and TGF‐β in serum were also detected by ELISA (R&D, Minneapolis, MN, USA). The process of ELISA was performed by the manufacturer's instruction.

Quantitative reverse transcription‐PCR (qRT‐PCR) analysis

RNA extraction from tissue and qRT‐PCR analysis were performed as described previously 15.

Western blot

The western blot was performed as previously described. Primary antibodies used for this analysis were as follows: GAPDH (1 : 4000; Cell Signaling Technology, Beverly, MA, USA), Smad‐3, p‐Smad‐3 (1 : 1000; Cell Signaling Technology), TGF‐β (1 : 1000; Abcam plc, Cambridge, UK), and visualized using Image Quant LAS 4000 (GE Healthcare, Little Chalfont, UK).

Statistical analysis

Results were expressed as means ± SD. Statistical significance was determined by ANOVA for comparisons of multiple means, Student's t‐test, or Mann–Whitney U‐test. Correlations were determined by Spearman's ranking. P < 0.05 was considered statistically significant.

Results

Skin fibrosis in Rag‐2‐KO mice induced by intravenous injection of B10.D2 mouse‐derived splenocytes

The skin is the most frequently involved organ in SSc, which mainly exhibits collagen overproduction and fibrosis 16. In our study, 4 × 107 splenocytes derived from B10.D2 mouse were injected intravenously into recipient BALB/c Rag‐2‐KO mice, and splenocytes derived from BALB/c mouse were injected for the control group.

Our result showed that experimental scl‐GvHD mice developed skin thickening and hardening with hair loss 3 weeks after injection with B10.D2 mouse‐derived splenocytes. The involved area of skin sclerosis gradually increased, and serious skin sclerosis and hair loss were detected 9 weeks after transplantation (Fig. 1A). Meanwhile, the mice weight decreased with the progress of the disease (Fig. 1B). scl‐GvHD mice began to die from 6 week after injection with 4 × 107 splenocytes derived from B10.D2 mouse; about 20% Scl‐GvHD mice died at 9 weeks after transplantation (Fig. 1C). The control group injected with splenocytes derived from BALB/c mouse did not show any skin sclerosis, hair loss, and death, but there was no statistical significance between two groups in terms of survival rate.

Figure 1.

Figure 1

Open in a new tab

Skin injuries, body weight changes, and survival in Rag‐2‐KO mice induced by intravenous injection of B10.D2 mouse‐derived splenocytes. (A) Skin sclerosis and hair loss involvement of the scl‐GvHD mice at 3, 6, and 9 weeks after transplantation. (B) The weight changes in scl‐GvHD mice and control mice. (C) The survival rate of scl‐GvHD mice and control mice; there is no statistical significance between two groups (P = 0.073). Ten mice were used in this experiment (control, n = 4; scl‐GvHD, n = 6).

Histological examination revealed marked dermal and subcutaneous tissue sclerosis, inflammatory cells infiltration, and skin appendages and fat tissue atrophy in upper back skin of scl‐GvHD mice (Fig. 2A: left 1st row and Fig. 2B: upper row, left column). Masson's trichrome staining further proved significant collagen deposition from 3 weeks after transplantation (Fig. 2A: right 1st row, 2nd column and Fig. 2B: lower row, left column). Dermal thickening declined because of skin appendages and fat tissue atrophy. More collagen deposition and connective tissue accumulation could be detected at 9 weeks (Fig. 2A: right 1st row, 3rd column and Fig. 2B: lower row, left column). Skin dermal sclerosis and collagen deposition are the characteristics of SSc. These data significantly proved that skin appendages, fat tissue atrophy, and collagen deposition in dermal and subcutaneous tissues could be induced in Rag‐2‐KO mice by intravenous injection of B10.D2 mouse‐derived splenocytes.

Figure 2.

Figure 2

Open in a new tab

Tissue inflammation, fibrosis, extensive fibrosis, and collagen deposition in scl‐GvHD mice. (A) H&E staining and Masson's trichrome staining of upper back skin, ear, kidney (cortex, medulla), lung, and liver in control mice and scl‐GvHD mice after splenocytes transplantation of 3 and 9 weeks. Scale bars represent 100 μm. (B) The results of the quantification of relative dermal and hypodermal layers thickness in skin, lung, and liver fibrosis, relative hydroxyproline content in skin, kidney, lung, and liver. Data are the means ± SEM (n = 3–5). P < 0.05, P < 0.01 compared with the corresponding value of the control. Twelve mice were used in this experiment (control, n = 4; scl‐GvHD, n = 8).

Extensive fibrosis in Rag‐2‐KO mice induced by intravenous injection of B10.D2 mouse‐derived splenocytes

In a systemic model for SSc, dermal thickening and collagen deposition were major manifestations, and in this study, these symptoms were found in skin as well as in ear (Fig. 2A: 2nd row). In addition, SSc has extensive involvement, such as intestinal tract, kidney, liver, and lung. Using HE and Masson's trichrome staining, in our scl‐GvHD model, collagen overproduction and increased infiltration of inflammatory cells were detected not only in liver, kidney cortex and medulla but also in lung tissue (Fig. 2A: 3rd, 4th, 5th, and 6th row, and Fig. 2B). Furthermore, our immunofluorescence data showed that overexpression of collagen‐I also could be detected in skin, kidney, but the most significantly increased in lung tissue (Fig. 3A, upper left and 3B).

Figure 3.

Figure 3

Open in a new tab

Collagen‐I and α‐SMA expression, T cells, and macrophages in scl‐GvHD mice. (A) Collagen‐I expression in upper back skin, ear, kidney, and lung tissues of control and scl‐GvHD mice after splenocytes transplantation of 3 and 9 weeks. Scale bars represent 100 μm. (B) The results of the quantification of fold change in collagen, α‐SMA, T cells, and macrophages in skin, ear, kidney, and lung. Data are the means ± SEM (n = 3–5). P < 0.05, P < 0.01 compared with the corresponding value of the control. Twelve mice were used in this experiment (control, n = 4; scl‐GvHD, n = 8).

Immunofluorescence staining for the detection of α‐SMA expression was performed to characterize additively the vascular changes in the murine scl‐GvHD model. As shown in Fig. 3A (upper right) and 3B, α‐SMA mainly expresses on activated fibroblasts and more α‐SMA‐positive cells were found in ear skin and lung tissue of scl‐GVHD mice. All these data proved that fibrosis not only involved the skin but also internal organs, especially lung tissue in our scl‐GvHD mice.

Immune cells infiltration, autoantibody, and inflammatory cytokines expression are increased in Scl‐GvHD model

Complex inflammatory cell infiltration in the skin is the symptom of scl‐GvHD model. Our data showed increased CD4+ T lymphocytes and F4/80+ macrophages infiltration in upper back skin, ear, kidney, and lung with the progress of disease activity (Fig. 3A, lower and 3B). These data indicate that immune cells infiltration was involved in the course of scl‐GvHD model; the scl‐GvHD model has the characteristics of immune cell dysfunction.

Anti‐topoisomerase antibody I (Scl‐70) is known as a hallmark antibody of SSc 1. We found that the serum concentration of anti‐Scl‐70 antibody was increased in the scl‐GvHD model compared with that in the control group (Fig. 4A). Furthermore, we examined the fibrosis‐related cytokines in our scl‐GVHD model. Our data showed that the serum concentration of IL‐10 was significantly increased and TGF‐β had the trend of elevation in scl‐GVHD model (Fig. 4A).

Figure 4.

Figure 4

Open in a new tab

Autoantibody and inflammatory cytokines related to fibrosis expression, and the gene expression of collagen synthesis and deposition, vascular change, inflammatory factors in scl‐GvHD mice. (A) Serum amounts of the Scl‐70 antibody, TGF‐β, and IL‐10 in scl‐GvHD mice at 3 and 9 weeks. The data shown are the means ± SD. P < 0.05, P < 0.01 compared with the corresponding value of the control; n = 6 in each group. (B) The mRNA expression of TNF‐α, IL‐6, TGF‐β, and collagen‐I genes in skin, kidney, and lung of the control and scl‐GvHD mice after splenocytes transplantation of 3 and 9 weeks. The relative quantity is presented as the ratio of the comparative cycle threshold (Ct) of the target genes against those of the housekeeping gene, 18S. Data are representative of three independent experiments and indicate the mean ratio of triplicate results from each experiment. Data are the means ± SEM (n = 3–5).

Meanwhile, we also detected gene expression of inflammatory factors, viz. tumor necrosis factor (TNF)‐α and IL‐6 as well as fibrosis‐related factors, that is, collagen‐I, TGF‐β, in skin, kidney, and lung tissues (Fig. 4B). The mRNA expression of TNF‐α showed tendency of elevation after the induction of SSc. IL‐6 was significantly increased especially in the kidney. TGF‐β mRNA expression also had trend of elevation similar to serum concentration. Expression of collagen‐I was found to increase significantly, especially in lung.

TGF‐β/Smad‐3 signal pathway related to fibrosis in Scl‐GvHD mouse model

As TGF‐β is a central player in fibrosis, we examined the expression of the TGF‐β and phosphorylated Smad‐3 that is signaling molecule of TGF‐β in the tissue. We found that TGF‐β was significantly overexpressed in the skin and lung, with a tendency of higher expression in kidney of scl‐GvHD mice (Fig. 5). In addition, significant Smad‐3 phosphorylation could be detected in the skin, kidney, and lung of scl‐GvHD mice, and Smad‐3 phosphorylation increased with disease progression (Fig. 5). These data suggested that TGF‐β/Smad‐3 signal pathway plays a key role in the fibrosis of scl‐GvHD mice.

Figure 5.

Figure 5

Open in a new tab

Expression of TGF‐β and phosphorylated Smad‐3 in scl‐GvHD mice. TGF‐β, Smad‐3, and p‐Smad‐3 protein expression in skin, kidney, and lung of scl‐GvHD mice after splenocytes transplantation of 3 and 9 weeks were detected by a western blot analysis. Data are the means ± SEM (n = 3–5). P < 0.05, P < 0.01 compared with the corresponding value of the control.

Discussion

In this study, we demonstrated that intravenous injection of spleen cells from B10.D2 donor mice into immunodeficient Rag‐2 recipient mice on the BALB/c genetic background could induce severe fibrosis of the skin and internal organs such as the kidney and lung. Anti‐Scl‐70 antibody is known as a hallmark antibody of diffuse systemic scleroderma, and anti‐Scl‐70 antibody is associated with more severe scleroderma disease 1, 17. In our study, anti‐Scl‐70 antibody could be detected and increased with the progress of disease activity in scl‐GvHD mice model. Traditional scl‐GVHD model indicates lung fibrosis involvement. Our data proved that obvious lung fibrosis could be detected in the modified scl‐GvHD model. Severe fibrosis of the skin and internal organs, including kidney and lung, could be detected in our scl‐GvHD mice model, which is different from the previous scl‐GvHD model established by Ruzek et al. 18, which was characterized by severe fibrosis of the skin and internal organs, but excluding the lung.

Overproduction of collagen by fibroblast is a key feature of SSc; increased synthesis of collagen indicated fibroblast activation. Excessive collagen deposition and microvascular injury were pathologic hallmarks of SSc. However, the most of mechanisms of these pathogenic changes remain unclear.

Long‐standing observation of several types of lymphocytes infiltration into the skin and lungs of patients with SSc suggested that SSc is an immune‐mediated disease 19, 20. Early infiltration of mononuclear cells that are primarily of T lymphocytes and macrophages into the skin has been reported 20. Furthermore, the degree and progression of skin thickening were well correlated with the extent of mononuclear cell infiltration in the skin of patients with SSc 20. As consistent with previous study, our data also showed that increased infiltration of CD4+ T cells and F4/80+ macrophages could be detected in back skin, ear, kidney, and lung with the progress of disease course. These results indicate the role of inflammatory cells in the etiology of SSc on the top of the diverse mechanisms in which it may be an important pathogenetic factor for the disease. Although the role of these cells in the course of fibrosis in SSc is not clearly understood, inflammatory cytokines produced by these inflammatory cells can induce fibroblast collagen production and fibrosis.

Consistent with this speculation, TGF‐β and IL‐10, two strong profibrotic factors, were highly expressed in serum and in tissues of skin, kidney, and lung in the scl‐GvHD model. Furthermore, collagen deposition was observed in skin, kidney, and lung, and mRNA expression of collagen‐I also elevated in scl‐GVHD model. In accordance, the number of cells expressed α‐SMA, which was known to express extracellular matrix including collagen‐I, was increased.

TGF‐β and TNF‐α are associated with collagen synthesis and deposition, vascular change, inflammatory factors infiltration, and are also involved in the pathogenesis. In particular, TGF‐β is a central player in fibrosis, serving to the influx and activation of inflammatory cells, and an elaboration of extracellular matrix followed endothelial–mesenchymal transition and the influx of fibroblasts 21, 22. In addition to other models of fibrosis 23, TGF‐β works as a massive irritation to elevated collagen synthesis, which is assumed to be definitive in the pulmonary and cutaneous fibrosis in scleroderma 24. TGF‐β is secreted by several types of cells such as endothelial cells, fibroblasts, and monocytes and can be switched to the active form by matrix metalloproteinases expressed by monocytes/macrophages. TGF‐β/Smad‐3 pathway is a key pathway for the activation of fibroblast and collagen production 25, 26. In our scl‐GVHD model, elevation of serum and tissue TGF‐β expression along with mRNA expression of TGF‐β in tissue was observed. Furthermore, Smad‐3 is a key downstream signal protein of TGF‐β 25. We found that obvious Smad‐3 phosphorylation could be detected in skin, kidney, and lung of the scl‐GvHD model, which indicated that the TGF‐β/Smad‐3 pathway played a key role in the pathogenesis of the scl‐GvHD model.

IL‐10 acts as an anti‐inflammatory cytokine, which is expressed by monocytes and lymphocytes. Some study showed that IL‐10 might play important role in SSc susceptibility 27, 28. In our scl‐GVHD model, IL‐10 secretion was significantly increased. Furthermore, TNF‐α and IL‐6 act as strong pro‐inflammatory cytokines, also highly expressed in skin, kidney, and lung. Increased expression of these pro‐inflammatory cytokines can further induce fibroblast activation, collagen synthesis, and fibrosis. Thus, blocking these pro‐inflammatory cytokines might be a promising therapy for the treatment of SSc.

Scl‐GvHD mice showed generalized inflammation and tissue fibrosis that closely resembled the inflammatory phase of diffuse SSc. Scl‐GvHD model using Rag‐2‐KO mice is suitable for SSc research rather than traditional model, as radiation before transplantation is unnecessary. In Ruzek et al.'s study, however, there was little evidence of lung fibrosis compared with traditional scl‐GvHD using radiation 8, 18, 29. As reviewed by Greenblatt and Aliprantis 29, one possible explanation is that inflammatory ‘danger’ signals, such as those elicited by radiation injury, are important for the induction of a program that elicited fibrosis and inflammatory in the scl‐GvHD lung. However, a significant proportion of patients with SSc have fibrosis of the heart, kidney, gastrointestinal tract, and lung 30, 31, 32. Furthermore, several known pulmonary manifestations have been reported in each subset of the disease 33 and, in fact, interstitial lung disease and pulmonary hypertension may occur more commonly in a SSc 34. Furthermore, pulmonary disease can occur even in SSc with no skin involvement (an entity known as scleroderma sine scleroderma) 35. Therefore, pathological change in lung is one of the important symptoms of SSc.

To improve the model to exhibit all major aspects of clinical characteristics of SSc, we used Rag‐2‐KO mouse from different vendors and substrains. Our donor strain in this study was B10.D2/nSnSlc from SLC, Inc, in Japan, while a previous study used B10.D2‐H2dH2‐T18CHC1/nSnJ from Jackson Laboratories in the USA. Furthermore, the background of Rag‐2−/− recipient is ‘BALB/cAJcl’ from CLEA Japan Inc. (Tokyo, Japan), whereas former study used same Rag‐2−/− but with BALB/cAnNTac background (C.129S6 [B6]‐Rag‐2tm1N12) obtained from Taconic Laboratories (Germantown, NY, USA).

BALB/c mice are an inbred strain and distributed globally, resulting in them being one of the most widely used inbred strains. Halsey J. Bagg originally established this strain as the ‘Bagg albino’ at the Memorial Hospital, New York, in 1913. George Davis Snell, who was a student of Hermann Joseph Muller, named the line BALB/c in 1932 36. Andervont and Friis bred the BALB/c mice independently and established BALB/cAn and BALB/cA, respectively. BALB/cAnN was developed from the BALB/cAn line by the National Institutes of Health 36.

Substrains have only minor genetic differences; however in certain kinds of situation, even the same strain from distinct animal breeders can also show major differences with respect to some phenotypes 37. Several studies demonstrated that the phenotype was different among substrains. Coletti et al. 38 showed that BALB/cAnNCrl, BALB/cByJ, and BALB/cJ display major differences in physical activity as a behavior. Ohta et al. 39 showed the substrain‐dependent sperm abnormalities in BALB/c mice using BALB/cByJ, BALB/cA, and BALB/cAnN. The BALB/cAnNHsd had lower toxicity and better survival and was more resistant to developing glucocorticoid‐induced osteonecrosis as compared with BALB/cJ 40. Furthermore, BALB/cByJ mice showed more continual and severe dystrophic cardiac calcinosis than do BALB/cJ and BALB/cAnTac 41. In the field of immunity and infection, the control of growth of Taenia crassiceps between BALB/cAnN and BALB/cJ substrains was different 42, 43. Furthermore, BALB/cJ mice were resistant to the induction of both experimental allergic encephalomyelitis and experimental allergic orchitis, whereas BALB/cByJ mice exhibited a nonfully penetrant, susceptible phenotype 44. In addition, even though among the same mouse strain, mice from different breeding colonies showed different immune profiles among them. Ivanov et al. demonstrated that CB57BL/6 mice from Jackson Laboratory had few Th17 cells in lamina propria of the small intestine, whereas CB57BL/6 mice from Taconic had significantly higher number of Th17 cells in lamina propria of the small intestine. It was caused by the difference in microbiota between the mice. 45. Potter and Wax 46 demonstrated that 20% of pristane‐treated BALB/cAn mice and 70% of pristane‐treated BALB/cJ mice develop arthritis, which was known to be T cell‐dependent onset 47. This study suggested that T cells from BALB/cJ mice have higher reactivity to self‐antigen than those from BALB/cAn mice. Furthermore, it is hypothesized that monocyte activation by host‐reactive T cells is an initiating event in scleroderma and human sclerodermatous chronic GvHD. Infiltrating monocytes in the skin produce TGF‐β, resulting in upregulation of Smad‐3 phosphorylation and collagen and leading to fibrosis 48, 49.

Taken together, our data have proved that transplantation of spleen cells into immunodeficient Rag‐2 recipients on the BALB/c background from B10.D2 donor mice could induce severe fibrosis of the skin and internal organs, including kidney and especially in lung, which ensures us to understand the etiology and pathophysiology of SSc based on the modeling.

Author contributions

XY and CL performed experiment. JY, XKL, and HZ designed experiment. CL, MF, and XKL analyzed data. CL, MF, and XKL wrote the manuscript.

Acknowledgements

This study was assisted in part by Research Grants 15K10043, 15K20303, and 15F15756 from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Grants 26‐6 from the National Center for Child Health and Development. This work was also supported by grants from National Natural Science Foundation of China (No. 81373213; 81401346; 81472874) and Program of Shanghai Subject Chief Scientist (No. 11XD1401100). We would like to thank Dr Julian Tang of the Department of Education for Clinical Research, National Center for Child Health and Development, for proofreading and editing this article.

Contributor Information

Xiao‐Kang Li, Email: ri-k@ncchd.go.jp.

Hejian Zou, Email: hjzou@fudan.edu.cn.

References

  • 1. Geyer M and Muller‐Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40, 92–103. [DOI] [PubMed] [Google Scholar]
  • 2. Broen JC, Radstake TR and Rossato M (2014) The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 10, 671–681. [DOI] [PubMed] [Google Scholar]
  • 3. Asano Y (2014) [A unifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 – the development of a new animal model of systemic sclerosis ‐]. Nihon Rinsho Meneki Gakkai Kaishi 37, 475–487. [DOI] [PubMed] [Google Scholar]
  • 4. Chizzolini C and Boin F (2015) The role of the acquired immune response in systemic sclerosis. Semin Immunopathol 37, 519–528. [DOI] [PubMed] [Google Scholar]
  • 5. Fullard N and O'Reilly S (2015) Role of innate immune system in systemic sclerosis. Semin Immunopathol 37, 511–517. [DOI] [PubMed] [Google Scholar]
  • 6. Yamamoto T (2010) Animal model of systemic sclerosis. J Dermatol 37, 26–41. [DOI] [PubMed] [Google Scholar]
  • 7. Morin F, Kavian N and Batteux F (2015) Animal models of systemic sclerosis. Curr Pharm Des 21, 2365–2379. [DOI] [PubMed] [Google Scholar]
  • 8. Beyer C, Schett G, Distler O and Distler JH (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62, 2831–2844. [DOI] [PubMed] [Google Scholar]
  • 9. Gratwohl AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB and Deisseroth AB (1977) Sjogren‐type syndrome after allogeneic bone‐marrow transplantation. Ann Intern Med 87, 703–706. [DOI] [PubMed] [Google Scholar]
  • 10. McCormick LL, Zhang Y, Tootell E and Gilliam AC (1999) Anti‐TGF‐beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft‐versus‐host disease: a model for human scleroderma. J Immunol 163, 5693–5699. [PubMed] [Google Scholar]
  • 11. Cai S, Ichimaru N, Zhao M, Fujino M, Ito H, Ota U, Nakajima M, Tanaka T, Nonomura N, Li XK et al (2016) Prolonged mouse cardiac graft cold storage via attenuating ischemia‐reperfusion injury using a new antioxidant‐based preservation solution. Transplantation 100, 1032–1040. [DOI] [PubMed] [Google Scholar]
  • 12. Hou J, Zhang Q, Fujino M, Cai S, Ito H, Takahashi K, Abe F, Nakajima M, Tanaka T, Xu J et al (2015) 5‐Aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells. J Heart Lung Transplant 34, 254–263. [DOI] [PubMed] [Google Scholar]
  • 13. Nishio Y, Fujino M, Cai S, Kitajima Y, Saito T, Tsumura H, Ito M, Ito Y, Nagahara Y and Li XK (2016) Impaired CD98 signaling protects against graft‐versus‐host disease by increasing regulatory T cells. Transpl Immunol 35, 34–39. [DOI] [PubMed] [Google Scholar]
  • 14. Desallais L, Avouac J, Frechet M, Elhai M, Ratsimandresy R, Montes M, Mouhsine H, Do H, Zagury JF and Allanore Y (2014) Targeting IL‐6 by both passive or active immunization strategies prevents bleomycin‐induced skin fibrosis. Arthritis Res Ther 16, R157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Luo XY, Takahara T, Hou JG, Kawai K, Sugiyama T, Tsukada K, Takemoto M, Takeuchi M, Zhong L and Li XK (2012) Theaflavin attenuates ischemia‐reperfusion injury in a mouse fatty liver model. Biochem Biophys Res Comm 417, 287–293. [DOI] [PubMed] [Google Scholar]
  • 16. Katsumoto TR, Whitfield ML and Connolly MK (2011) The pathogenesis of systemic sclerosis. Annu Rev Pathol 6, 509–537. [DOI] [PubMed] [Google Scholar]
  • 17. Le Thi H, Sauvaget F, Johanet C, De Gennes C, Raguin G, Abuaf N, Bletry O, Guillevin L, Homberg JC and Godeau P (1990) Anti‐Scl‐70 antibodies in systemic scleroderma. Ann Dermatol Venereol 117, 103–107. [PubMed] [Google Scholar]
  • 18. Ruzek MC, Jha S, Ledbetter S, Richards SM and Garman RD (2004) A modified model of graft‐versus‐host‐induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50, 1319–1331. [DOI] [PubMed] [Google Scholar]
  • 19. White B (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 22, 695–708. [DOI] [PubMed] [Google Scholar]
  • 20. Roumm AD, Whiteside TL, Medsger TA Jr and Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27, 645–653. [DOI] [PubMed] [Google Scholar]
  • 21. Chen C, Akiyama K, Wang D, Xu X, Li B, Moshaverinia A, Brombacher F, Sun L and Shi S (2015) mTOR inhibition rescues osteopenia in mice with systemic sclerosis. J Exp Med 212, 73–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Pang MF, Georgoudaki AM, Lambut L, Johansson J, Tabor V, Hagikura K, Jin Y, Jansson M, Alexander JS, Nelson CM et al (2016) TGF‐beta1‐induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21‐mediated chemotaxis. Oncogene 35, 748–760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Baraut J, Farge D, Jean‐Louis F, Masse I, Grigore EI, Arruda LC, Lamartine J, Verrecchia F and Michel L (2015) Transforming growth factor‐beta increases interleukin‐13 synthesis via GATA‐3 transcription factor in T‐lymphocytes from patients with systemic sclerosis. Arthritis Res Ther 17, 196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Zerr P, Vollath S, Palumbo‐Zerr K, Tomcik M, Huang J, Distler A, Beyer C, Dees C, Gela K, Distler O et al (2015) Vitamin D receptor regulates TGF‐beta signalling in systemic sclerosis. Ann Rheum Dis 74, e20. [DOI] [PubMed] [Google Scholar]
  • 25. Zerr P, Palumbo‐Zerr K, Huang J, Tomcik M, Sumova B, Distler O, Schett G and Distler JH (2016) Sirt1 regulates canonical TGF‐beta signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis 75, 226–233. [DOI] [PubMed] [Google Scholar]
  • 26. Tomcik M, Palumbo‐Zerr K, Zerr P, Avouac J, Dees C, Sumova B, Distler A, Beyer C, Cerezo LA, Becvar R et al (2015) S100A4 amplifies TGF‐beta‐induced fibroblast activation in systemic sclerosis. Ann Rheum Dis 74, 1748–1755. [DOI] [PubMed] [Google Scholar]
  • 27. Dziankowska‐Bartkowiak B, Zalewska A and Sysa‐Jedrzejowska A (2004) Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL‐10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients. Med Sci Monit 10, CR202‐8. [PubMed] [Google Scholar]
  • 28. Hikami K, Ehara Y, Hasegawa M, Fujimoto M, Matsushita M, Oka T, Takehara K, Sato S, Tokunaga K and Tsuchiya N (2008) Association of IL‐10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem Biophys Res Comm 373, 403–407. [DOI] [PubMed] [Google Scholar]
  • 29. Greenblatt MB and Aliprantis AO (2013) The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep 15, 297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Medsger TA (1993) Systemic sclerosis (scleroderma), localized forms of scleroderma and calcinosis In Arthritis and Allied Conditions (McCarty DJ. and Koopman WJ, eds), 12th edn, pp. 1253–1292. Lea & Febiger, Philadelphia, PA. [Google Scholar]
  • 31. Seibold JR (1997) Scleroderma In Textbook of Rheumatology (Kelley WN, Harris ED, Ruddy S. and Sledge CB, eds), pp. 1133–1162. W.B. Saunders Company, Philadelphia, PA. [Google Scholar]
  • 32. Steen VD and Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43, 2437–2444. [DOI] [PubMed] [Google Scholar]
  • 33. Highland KB, Garin MC and Brown KK (2007) The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 28, 418–429. [DOI] [PubMed] [Google Scholar]
  • 34. Morelli S, Barbieri C, Sgreccia A, Ferrante L, Pittoni V, Conti F, Gualdi G, Polettini E, Carlesimo OA and Calvieri S (1997) Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 24, 81–85. [PubMed] [Google Scholar]
  • 35. Toya SP and Tzelepis GE (2009) The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 29, 861–868. [DOI] [PubMed] [Google Scholar]
  • 36. Potter M (1985) History of the BALB/c family. Curr Top Microbiol Immunol 122, 1–5. [DOI] [PubMed] [Google Scholar]
  • 37. Graham ML, Janecek JL, Kittredge JA, Hering BJ and Schuurman HJ (2011) The streptozotocin‐induced diabetic nude mouse model: differences between animals from different sources. Comp Med 61, 356–360. [PMC free article] [PubMed] [Google Scholar]
  • 38. Coletti D, Berardi E, Aulino P, Rossi E, Moresi V, Li Z and Adamo S (2013) Substrains of inbred mice differ in their physical activity as a behavior. ScientificWorldJournal 2013, 237260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Ohta H, Sakaide Y and Wakayama T (2009) Age‐ and substrain‐dependent sperm abnormalities in BALB/c mice and functional assessment of abnormal sperm by ICSI. Hum Reprod 24, 775–781. [DOI] [PubMed] [Google Scholar]
  • 40. Kawedia JD, Janke L, Funk AJ, Ramsey LB, Liu C, Jenkins D, Boyd KL and Relling MV (2012) Substrain‐specific differences in survival and osteonecrosis incidence in a mouse model. Comp Med 62, 466–471. [PMC free article] [PubMed] [Google Scholar]
  • 41. Glass AM, Coombs W and Taffet SM (2013) Spontaneous cardiac calcinosis in BALB/cByJ mice. Comp Med 63, 29–37. [PMC free article] [PubMed] [Google Scholar]
  • 42. Fragoso G, Lamoyi E, Mellor A, Lomeli C, Hernandez M and Sciutto E (1998) Increased resistance to Taenia crassiceps murine cysticercosis in Qa‐2 transgenic mice. Infect Immun 66, 760–764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Lopez‐Briones S, Lamoyi E, Fragoso G, Soloski MJ and Sciutto E (2003) Taenia crassiceps cysticercosis: immune response in susceptible and resistant BALB/c mouse substrains. Parasitol Res 90, 236–242. [DOI] [PubMed] [Google Scholar]
  • 44. Teuscher C, Hickey WF, Grafer CM and Tung KS (1998) A common immunoregulatory locus controls susceptibility to actively induced experimental allergic encephalomyelitis and experimental allergic orchitis in BALB/c mice. J Immunol 160, 2751–2756. [PubMed] [Google Scholar]
  • 45. Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB and Littman DR (2008) Specific microbiota direct the differentiation of IL‐17‐producing T‐helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Potter M and Wax JS (1981) Genetics of susceptibility to pristane‐induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane‐induced arthritis. J Immunol 127, 1591–1595. [PubMed] [Google Scholar]
  • 47. Stasiuk LM, Ghoraishian M, Elson CJ and Thompson SJ (1997) Pristane‐induced arthritis is CD4+ T‐cell dependent. Immunology 90, 81–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Zhang Y, McCormick LL, Desai SR, Wu C and Gilliam AC (2002) Murine sclerodermatous graft‐versus‐host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168, 3088–3098. [DOI] [PubMed] [Google Scholar]
  • 49. Bu S, Asano Y, Bujor A, Highland K, Hant F and Trojanowska M (2010) Dihydrosphingosine 1‐phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum 62, 2117–2126. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from FEBS Open Bio are provided here courtesy of Wiley

RESOURCES